建模全身动态PET微剂量数据,以预测GLYBURIDE在人类中的全身药理动力学
相关实验视频
Updated: Jan 17, 2026

07:07
Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
Published on: May 2, 2017
14.3K
Léa Comin1,2, Solène Marie2,3, Moreno Ursino1
1Inserm, UMRS 1346, Université Paris Cité, Inria, HeKA, 75015, Paris, France.
Clinical pharmacokinetics
|September 17, 2025
概括
这项研究从[11C]glyburide的全身动态PET成像开发了一个药理动力学模型. 该模型准确地描述了糖的生物分布和药物相互作用,通过PET数据推进了PK分析.
科学领域:
- 药理动力学和药物新陈代谢
- 核医学和成像技术
- 量化系统药理学 药理学
背景情况:
- 全身动态 (WB4D) PET成像在定量药理动力学 (PK) 分析中未得到充分利用.
- 传统的PK研究依赖于血液采样,缺乏空间生物分布信息.
- 放射性标记药物类似物提供了一种非侵入性方法来研究药物处置.
研究的目的:
- 开发和验证使用人类[11C]甘化物WB4DPET数据的PK模型.
- 描述草甘的生物分布和动力学.
- 将PET数据估计的PK参数与传统PK研究中的PK参数进行比较.
主要方法:
- 非线性混合效应建模 (NLMEM) 应用于来自16名健康受试者的WB4D PET数据.
- 数据是在注射[11C]甘化物后40分钟获得的.
- 在10名受试者中进行了一项药物相互作用研究,以评估其对肝脏吸收的影响.
主要成果:
- 开发了一个七个隔间模型,包括用于肝脏和脏组织交换的特定隔间.
- 里芬素的使用显著降低了glyburide的肝脏分布261%.
- 该模型成功地将PET成像数据与PK原理集成在一起.
结论:
- 来自[11C]甘化物WB4D PET数据的PK模型产生了与已知的甘化物药理动力学相一致的参数.
- 这种方法表明了利用微剂量PET数据用于定量生物分布研究的潜力.
- 这些发现支持使用WB4D PET进行非侵入性PK评估和药物相互作用研究.
相关概念视频
Model Approaches for Pharmacokinetic Data: Physiological Models
249
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
249
Pharmacokinetic Models: Comparison and Selection Criterion
338
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
338
Pharmacokinetic Models: Overview
1.9K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.9K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
242
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
242
Dosage Regimens: Partial Pharmacokinetic Parameters
155
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
278
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
278

